MGD014
/ MacroGenics
- LARVOL DELTA
Home
Next
Prev
1 to 9
Of
9
Go to page
1
October 17, 2025
The DART DELIVER-02 Study
(clinicaltrials.gov)
- P1 | N=24 | Recruiting | Sponsor: University of North Carolina, Chapel Hill
New P1 trial • Human Immunodeficiency Virus • Infectious Disease
June 26, 2024
A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral Therapy
(clinicaltrials.gov)
- P1 | N=24 | Completed | Sponsor: MacroGenics | Active, not recruiting ➔ Completed | N=54 ➔ 24
Combination therapy • Enrollment change • Trial completion • Human Immunodeficiency Virus • Infectious Disease • CD4
April 19, 2024
A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral Therapy
(clinicaltrials.gov)
- P1 | N=54 | Active, not recruiting | Sponsor: MacroGenics | Recruiting ➔ Active, not recruiting
Combination therapy • Enrollment closed • Human Immunodeficiency Virus • Infectious Disease • CD4
August 24, 2023
A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral Therapy
(clinicaltrials.gov)
- P1 | N=54 | Recruiting | Sponsor: MacroGenics | Trial completion date: Jul 2023 ➔ Mar 2024 | Trial primary completion date: Jul 2023 ➔ Mar 2024
Combination therapy • Trial completion date • Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease • CD4 • IL10 • IL2 • IL5 • IL6
August 24, 2022
A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral Therapy
(clinicaltrials.gov)
- P1 | N=54 | Recruiting | Sponsor: MacroGenics | Not yet recruiting ➔ Recruiting
Combination therapy • Enrollment open • Human Immunodeficiency Virus • Immunology • Infectious Disease • CD4 • IL10 • IL2 • IL5 • IL6
May 12, 2022
In vivo preclinical efficacy of MGD014 and MGD020 (HIV-1 envelope x CD3 DART molecules) and first-in-human phase 1 clinical safety evaluation of MGD014
(AIDS 2022)
- P1 | "Administration of MGD020+MGD014 mediated greater HIV-1 clearance activity than individual DART molecules in HIV-1-infected humanized mice. MGD014 was well-tolerated in PWH on ART. A first-in-human study with MGD020+MGD014 in PWH on ART will begin in 2022.Our data support future clinical studies combining DART molecules and latency reversing agents."
P1 data • Preclinical • Human Immunodeficiency Virus • Infectious Disease • CD4 • CD8
March 02, 2022
A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral Therapy
(clinicaltrials.gov)
- P1 | N=54 | Not yet recruiting | Sponsor: MacroGenics
Combination therapy • New P1 trial • Human Immunodeficiency Virus • Immunology • Infectious Disease • CD4 • IFNG • IL10 • IL2 • IL5 • IL6 • TNFA
October 20, 2021
MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy
(clinicaltrials.gov)
- P1; N=24; Completed; Sponsor: MacroGenics; Recruiting ➔ Completed
Clinical • Trial completion • Human Immunodeficiency Virus • Immunology • Infectious Disease • CD4
August 28, 2020
MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy
(clinicaltrials.gov)
- P1; N=26; Recruiting; Sponsor: MacroGenics; Trial completion date: Mar 2020 ➔ Oct 2021
Trial completion date • Human Immunodeficiency Virus • Immunology • Infectious Disease
1 to 9
Of
9
Go to page
1